SUPERNOVA

Purpose

This study is looking at a new medication to evaluate its safety and if it can help protect people with an impaired immune system from contracting COVID-19.

Description

The medication in this study is an investigational monoclonal antibody. Antibodies are protein molecules made naturally in the body that help fight infection. Monoclonal antibodies are made in a laboratory. They act like natural antibodies and are designed as possible medical treatments. The treatment in this study is investigational, which means it is still being tested and it not available for doctors to prescribe to patients in the general public.

Participants who are eligible will be in the study for about 15 months. This includes follow up visits at the study center and over the phone. Extra visits may be required if a participant develops COVID-19 symptoms. The study medication is a single intramuscular injection, or “shot” in the thigh muscle given at two different visits, 6 months apart. Participants enrolled in the study will be randomly assigned to the study medication or placebo, a non-active treatment option.

The responsibilities of the enrolled participants include but are not limited to following all instructions given during the study, attend all study visits, and alerting the study team of any medications, immunizations, or treatments received at any point during the study. It is also important to notify the study team of any symptoms or changes that occur while you are a participant in the study.